Vicuron Pharmaceuticals, King of Prussia, Pennsylvania Dalbavancin, a novel glycopeptide with a long elimination half-life (∼9-12 days), was compared to standard antimicrobial therapy for skin and soft-tissue infections (SSTIs). In a randomized, controlled, open-label, phase 2 proof-of-concept trial, adults received 1100 mg of dalbavancin (as a single intravenous infusion), 1000 mg of dalbavancin intravenously and then 500 mg intravenously 1 week later, or a prospectively defined standardof-care regimen. A gram-positive pathogen was isolated from samples obtained from 41 (66%) of 62 patients at baseline; Staphylococcus aureus was the most prevalent species (83% of pathogens). Clinical success rates at a follow-up visit (test of cure) were 94.1% among patients treated with 2 doses of dalbavancin, 61.5% among patients treated with 1 dose of dalbavancin, and 76.2% among patients treated with a standard-of-care regimen. All treatment regimens were well tolerated; drug-related adverse reaction rates were similar across the 3 groups. These findings suggest that a regimen of 2 doses of dalbavancin administered 1 week apart is effective in the treatment of complicated, gram-positive bacterial SSTIs and warrants further study.
. Although dalbavancin has the same mechanism of action as other glycopeptides (i.e., inhibition of cell-wall peptidoglycan cross-linking), it is not completely crossresistant with vancomycin. For example, dalbavancin is active against certain vancomycin-resistant enterococci (including VanB and VanC strains) [2] and is also active in vitro and in animal infection models against vancomycin-intermediate S. aureus strains [4] .
Dalbavancin MICs for target organisms are greatly exceeded during the entire treatment interval, because a unique feature of dalbavancin is its long elimination half-life (∼9-12 days in humans) [5] [6] [7] . This long halflife is the result of extensive, reversible binding of dalbavancin to plasma proteins, primarily albumin. The degree of plasma protein binding is constant through concentrations observed in clinical studies and has been estimated to be 195% by means of a number of quantitative methods [8] . After a single intravenous infusion of 1 g of dalbavancin, mean plasma concentrations were found to be 135 mg/L for 7 days. This dose was chosen for investigation of the dose needed to maintain con-centrations that exceed the MICs of target skin and soft-tissue infection (SSTI) pathogens for at least 1 week. These concentrations have been shown to be bactericidal for staphylococci [5] .
We report on the safety and efficacy of dalbavancin in a study of 1-and 2-dose regimens of dalbavancin versus standardof-care therapy in adults with SSTIs caused by gram-positive pathogens.
PATIENTS AND METHODS

Patient Population
Men and nonpregnant women у18 years of age who had an SSTI that was suspected or known to be caused by gram-positive bacteria (based on Gram staining or culture results) were eligible for enrollment. Eligible SSTIs were those that involved deep soft tissue and/or required significant surgical intervention, such as a major abscess, an infected ulcer, a major burn (р20% body surface area), or deep and extensive cellulitis. In addition, to be eligible for study inclusion, patients had to have at least 2 symptoms consistent with SSTI, including drainage, erythema, fluctuance, heat, tenderness to palpation, or swelling.
Exclusion criteria for this study included creatinine clearance !50 mL/min, receipt of recent antimicrobial treatment for SSTI (a regimen lasting 124 h within 7 days before study entry), self-limited infection, SSTI with compromised vascularity, and documented osteomyelitis. Because no information exists about vancomycin allergies and cross-reactivity with dalbavancin, patients with a history of glycopeptide hypersensitivity were excluded.
Study Design and Antimicrobial Regimens
The study, a randomized, controlled, open-label, phase 2 proofof-concept trial, was conducted at 10 centers in the United States from 31 July 2001 through 30 May 2002. Each center received protocol approval from its institutional review board, and written consent was obtained from each patient before receipt of study drug.
In this dose-ranging study, only descriptive statistics were prospectively planned. Assuming 80%-85% success rates, it was estimated that a treatment group size of ∼20 patients would provide 95% CIs for the true success rates, with the bounds of 95% CIs not 117.5%.
Sixty patients у18 years of age were to be enrolled. Before randomization, investigators determined the antimicrobial therapy that each patient would receive if he or she were randomized to the comparator arm. Subjects were then randomly assigned to 1 of 3 groups: 1-dose dalbavancin (a single 1100-mg dose of dalbavancin [Vicuron Pharmaceuticals] administered intravenously as a single dose), 2-dose dalbavancin (1 intravenous dose of 1000 mg of dalbavancin, followed by a second intravenous dose of 500 mg 1 week later [study day 8]), or a comparator regimen (determined by the investigator before randomization). Dalbavancin was administered intravenously over the course of a 30-min period. For study purposes, the end of therapy (EOT) was considered to be 10-12 days after the last dalbavancin dose, which is consistent with the drug's pharmacokinetics. The comparator antimicrobial regimens were administered for 7-21 days, and patients could be switched to oral therapy at the investigator's discretion. The investigator did not have to specify the intended duration of therapy for patients in the comparator group before randomization.
If the investigator determined that gram-negative aerobic or anaerobic bacterial coverage was needed, patients could also receive aztreonam, ceftazidime, or metronidazole. Assessments were performed at baseline, at the EOT visit (day 10 for 1-dose dalbavancin, day 20 for 2-dose dalbavancin, and on the last day of dosing for comparator regimens), and at the follow-up visit (day 24 for 1-dose dalbavancin, day 34 for 2-dose dalbavancin, and 2 weeks after the last dose for comparator regimens).
Clinical and Microbiologic Evaluations
At each visit, the investigator recorded the extent of infection, the depth of involvement, a description of the infected site, any underlying medical conditions (e.g., diabetes mellitus), and surgical interventions undergone, if any, since the last visit.
Specimens from the lesion were obtained for Gram staining and culture. For cellulitis, culture of a specimen from leadingedge needle aspiration was required. For complicated SSTIs, deep samples (e.g., fluids or pus obtained through biopsy or needle aspiration or surgically obtained specimens) from the infected site were recommended. Superficial swabs were not allowed. Blood samples were obtained for culture when clinically indicated. Culture, organism identification, and susceptibility testing were performed by each site's laboratory, and isolates were stored and sent to a central laboratory (JMI Laboratories; North Liberty, IA) for confirmation of the first laboratory's results, for determination of dalbavancin MICs, and for testing of susceptibility to other antibacterial agents.
Statistical Analysis
Populations for analysis. Four study populations were evaluated for safety and efficacy. Patients who received у1 dose of study drug were evaluated for safety (intent-to-treat [ITT] population). The microbiologic ITT population included all ITT patients for whom gram-positive pathogens were isolated from samples obtained at baseline. The clinically evaluable population included those who met study entry criteria and adhered to the study protocol. The microbiologically evaluable population was the subset of clinically evaluable patients who had gram-positive pathogens at baseline.
Responses. The effectiveness of the 3 treatment regimens was determined by assessing the patients' clinical and microbiologic responses. The prospectively defined primary efficacy end point was clinical response (cure, improvement, or failure) at the follow-up visit in the clinically evaluable population. Patients could not be classified as "cured" or "improved" if they had received additional systemic antibacterial treatment for the infection. "Failure" was defined as persistence of у1 systemic sign or symptom of SSTI that indicated a need for additional antibacterial therapy. Outcomes of cure and improvement were classified as "success"; for purposes of the ITT analysis, cases in which data were missing were classified as "failure."
Microbiologic outcome, a secondary efficacy variable, was assessed in patients who had a gram-positive pathogen at baseline. Outcomes for pathogens and patients at the EOT and follow-up visits were graded as "success" (pathogen was eradicated or was presumed to have been eradicated) or "failure" (pathogen persisted or was presumed to have persisted).
Pharmacokinetic analysis. Dalbavancin concentrations in plasma were measured on days 8, 10, and 24 and on days 8, 20, and 34 in the 1-dose group and the 2-dose group, respectively. Dalbavancin plasma concentrations were determined by a validated, bioanalytic assay that used mass spectrometry. The lower limit of quantitation of the assay was 0.5 mg/L. Safety evaluation. Patients who received у1 dose of study drug (ITT population) were evaluated for safety by monitoring of adverse events, vital signs, and laboratory parameters. The severity of adverse events (mild, moderate, severe, or life-threatening) and the relationship to the study drug were evaluated by the investigator, using criteria defined in the protocol. Laboratory data were analyzed for prospectively defined clinically significant changes. Specifically, laboratory values were examined for the percentage of patients with prospectively defined, clinically significant high and low hematologic and chemistry values, with clinically significant changes from baseline in these values, and with high and low values and changes from baseline.
RESULTS
Study population and therapy.
A total of 62 patients (20 who received the 1-dose dalbavancin regimen, 21 who received the 2-dose dalbavancin regimen, and 21 who received comparator regimens) were randomized and received у1 dose of study drug. The relevant populations for analysis are described in table 1. Reasons for exclusion from the clinically evaluable population were need for concomitant antibacterial agents (for reasons other than SSTI) and/or corticosteroids ( ), no n p 5 evidence of gram-positive pathogen found at baseline ( ), n p 3 missing EOT or follow-up visit ( ), and SSTI with comn p 2 promised vascularity ( ). Three patients (5%) did not n p 1 complete the study as planned, including 2 patients whose study participation was discontinued as a result of noncompliance (1 in each dalbavancin group) and 1 patient whose participation was discontinued because of receipt of treatment with a prohibited medication (1-dose dalbavancin group).
For the ITT population, the comparator regimens are listed in table 2. In the comparator group, 13 (65%) of 20 patients who initially received intravenous therapy were switched to oral therapy. The median length of comparator therapy was 15 days (range, 7-44 days).
In the clinically evaluable population, there were 13, 17, and 21 patients from the 1-dose dalbavancin group, the 2-dose dalbavancin group, and the comparator group, respectively. The treatment groups were comparable in terms of age and weight; the majority of patients were white. Most patients received diagnoses of deep or complicated infections. Approximately two-thirds of the patients underwent surgical intervention before randomization. More patients in the 2-dose dalbavancin group had diabetes and were female. Overall, these data were similar for the ITT population. Clinical efficacy. Clinical outcomes are summarized in table 1. Similar success rates at both EOT and follow-up assessments were found in all populations, with a consistent trend toward a more favorable response in the 2-dose dalbavancin group. Clinical success rates at the follow-up visit for patients infected with methicillin-resistant S. aureus were 80% (4 of 5 patients) for 2-dose dalbavancin, 50% (3 of 6 patients) for 1-dose dalbavancin, and 50% (1 of 2 patients) for the comparator regimens. None of the failures in the comparator group could be explained by lack of in vitro activity of the antibiotic against the isolated pathogen.
Microbiologic efficacy. Microbiologic outcomes are summarized in table 1. At follow-up, S. aureus eradication rates among microbiologically evaluable patients were higher for patients in the 2-dose dalbavancin group than for patients in the 1-dose dalbavancin and comparator groups. For isolates that persisted, there was no change in dalbavancin MIC.
Pharmacokinetics. Mean dalbavancin plasma concentrations are shown in table 4. Concentrations 130 mg/L were 
NOTE.
For "all patients randomized," n/N is no. of patients in a population/no. of patients who received the indicated treatment regimen. For "clinical success," n/N is no. of patients with clinical success/no. of patients in the indicated population who received the indicated treatment regimen. For "microbiological success," n/N is no. of pathogens eradicated/no. of pathogens detected. EOT, end-of-therapy; ITT, intent-to-treat.
a Comparator regimens were determined by investigators before randomization. b Microbiologic success rates were calculated for the group of patients with who were microbiologically evaluable at follow-up.
More than 1 pathogen was detected in some patients. Ceftriaxone alone or in combination 6
Cefazolin alone or in combination 4
Piperacillin and tazobactam in combination 3
Clindamycin alone 2
Vancomycin alone or in combination 4
Linezolid alone 1
Cephalexin alone 1
NOTE. Standard-of-care regimens were determined by investigators before randomization. maintained for 1 week after a single 1100-mg dose, and concentrations remained 120 mg/L for 20 days in patients who received 1000 mg on day 1 and 500 mg on day 8. Concentrations of dalbavancin for patients whose outcomes were categorized as failures were at least as high as those for patients whose outcomes were categorized as successes, which suggests that inadequate drug exposure was not the reason for failure.
Safety and tolerability. All patients who received у1 dose of study drug underwent safety assessments. The majority of patients (90%) experienced у1 adverse event, and most adverse events (90%) were considered to be mild to moderate in severity. All 8 serious adverse events (cellulitis, wound infection, congestive heart failure, myocardial infarction, asthma, toe amputation, dehydration, and foot ulcer; these events occurred in 5 patients) were considered to be unrelated to study drug. The investigator categorized adverse events as possibly or probably related to study drug in 59% of patients who reported adverse events. Specifically, drug-related adverse events were reported in 11 patients (55%) who received 1-dose dalbavancin, 10 patients (48%) who received 2-dose dalbavancin, and 12 patients (57%) who received comparator regimens. No clinically meaningful abnormal laboratory values were found, including serum creatinine levels, in any group. There were no discontinuations of study drug that resulted from an adverse event in the dalbavancin groups, and no patient left the study because of an adverse event. In the comparator group, 3 (14%) of 21 patients had treatment prematurely discontinued as a result of an adverse event, including 1 patient who developed urticaria on day 1 (probably drug related) and 2 patients who had adverse events reported as unrelated to study drug (superinfection with Pseudomonas aeruginosa and elevated vancomycin trough level).
DISCUSSION
This study provides the first evidence of efficacy for dalbavancin in the treatment of adults with SSTIs and provides proof of concept for infrequent dosing of dalbavancin. Most patients had deep or complicated infections (190% of patients), and most had infections that required surgical intervention (∼70% of patients).
The 2-dose dalbavancin regimen was associated with a numerically higher clinical response rate than was either the 1-dose dalbavancin regimen or the comparator regimens. These data suggest that a regimen of 2 doses of dalbavancin administered 1 week apart is effective in the treatment of complicated SSTIs. As in previous SSTI clinical trials [9] [10] [11] [12] , S. aureus was the organism most frequently isolated from samples obtained at baseline. In this trial, most patients were infected with S. aureus; 38% of all S. aureus strains were resistant to methicillin. The MICs for dalbavancin against gram-positive isolates, including methicillin-resistant S. aureus, are consistent with data reported elsewhere [1, 2] and consistently lower than MICs for vancomycin.
In this study, microbiologic success rates paralleled those of clinical response. For all organisms, treatment with the 2-dose dalbavancin regimen resulted in higher eradication rates at follow-up, compared with the 1-dose dalbavancin and comparator regimens. Although the overall numbers are small, eradication rates for S. aureus (both methicillin susceptible and methicillin resistant) infections after receipt of the 2-dose dalbavancin regimen in this study were generally higher (90%) than rates reported elsewhere (64%-89%), including in the literature for other compounds (quinupristin-dalfopristin, fluoroquinolones, and a new carbapenem) [9, 10, 13] . However, S. aureus eradication rates (60%) for comparator regimens used in this trial were similar to or slightly lower than those reported in other trials that evaluated the efficacy of b-lactams, vancomycin, and clindamycin for treatment of SSTIs (63%-81%) [9] [10] [11] [12] .
Plasma concentrations 130 mg/L were maintained for 1 week after a single 1100-mg dose of dalbavancin, and concentrations remained 120 mg/L for 20 days in patients who received the 2-dose dalbavancin regimen. Concentrations after the first and second dose were similar. Importantly, dalbavancin plasma levels measured 10-12 days after the second dose were well above the reported MIC 90 values for pathogens responsible for the majority of SSTIs (!0.03-0.5 mg/L) [1, 2] , including those found in this trial. Taking into account the degree of dalbavancin protein binding, the estimated concentration of free drug would also be similar to or greater than the MIC 90 values. Dalbavancin has been shown to have good tissue distribution and penetration in quantitative animal tissue distribution studies and in a granuloma pouch model of S. aureus infection [14] . Adverse reaction rates were similar in all treatment groups, and the majority of adverse events were mild. No dalbavancintreated patient had study participation discontinued because of an adverse event, and no serious adverse events were attributable to dalbavancin. This is consistent with the findings of phase 1 studies, in which dalbavancin was well tolerated [5] . As with earlier investigations, this study found no evidence that dalbavancin induces hepatotoxicity or nephrotoxicity. With dalbavancin, routine monitoring of serum concentrations may not be necessary, because dalbavancin appears to have a broad therapeutic index.
Although the preliminary findings with regard to the 2-dose dalbavancin regimen are encouraging, our study has several potential limitations. Because of its size, our ability to make statistical inferences about the results are limited. Because the treatment durations differed, the timing of efficacy assessments varied, and the visit schedule was dissimilar among the 3 treatment groups. In general, EOT and follow-up assessments for clinical and microbiologic response occurred earlier for the 1-dose dalbavancin group than for either the 2-dose dalbavancin group or the comparator group. This may have created some bias against the 1-dose dalbavancin regimen, in that signs and symptoms had less time to resolve before the investigator assessed outcome. The timing of the assessments varied greatly in the comparator group, which may have confounded comparisons of efficacy with the dalbavancin groups.
Despite these limitations, the 2-dose dalbavancin regimen appears to be effective for treatment of patients with complicated SSTIs. Both dalbavancin regimens were well tolerated, and the adverse event profiles were similar to that of the comparator group. This study suggests that a regimen of 2 doses of dalbavancin administered 1 week apart is a well-tolerated, practical, and effective option for the treatment of adult patients with deep SSTIs caused by gram-positive organisms. Phase 3 studies are under way to confirm the efficacy of dalbavancin in the treatment of patients with uncomplicated and complicated SSTIs.
